The Regeneron Pharmaceuticals (REGN) share price has seen a cooling period, leading experts to reassess its valuation. Successful results from an obesity Phase 3 trial are among positive developments, leading to increased favorability from analysts. Major institutional investors such as Dodge & Cox, Suvretta Capital Management, Game Creek Capital, and others, have diversified their stock holdings with REGN, demonstrating a belief in its uptrend. Despite a positive consensus recommendation from analysts, the company's narrative remains tentative as the market anticipates the changing impact of obesity data and Dupixent expansion efforts. Furthermore, a high-dose bet is reportedly paying off for Regeneron, despite the perceived weakness in its core Eylea offering. Analysts consider REGN as one of the top gene therapy stocks to buy, projecting a possibility of up to 60% upside returns. The firm's advances in obesity treatment have shown promise, although its shares fell in Q2. Additional pressure comes from an R&D surge and margin squeeze. Investors expect REGN to maintain its momentum given its continued rare disease focus and its 'Moderate Buy' recommendation from Wall Street. The FDA has also accepted a BLA from REGN for Garetosmab under priority review.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 14 Mar 2026 12:44:54 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -3
